|
Subcutaneous rituximab noninferior to IV formulation in follicular lymphoma
Healio Subcutaneous rituximab appeared noninferior to the IV formulation in patients with follicular lymphoma, conferring similar outcomes without increased safety issues, according to preliminary study results. The SABRINA study — a two-stage, randomized, … |
Science Codex |
B-cells aggravate autoimmune diseases
Science Codex In cases of rheumatoid arthritis in which conventional treatments are ineffective, patients can be treated with the drug Rituximab. The drug destroys all B-cells in the body and will thus at least halt the progress of the disease. “The B-cells produced … |
Cornell University The Cornell Daily Sun (blog)Weill Cornell Researchers Find a Better Alternative to Chemotherapy for LeukemiaCornell University The Cornell Daily Sun (blog)The double-blind, randomized, placebo-controlled study compared the efficacy o…
|
Investigation Report on China Rituximab Market, 2009-2018
The International News Magazine Reportstack has announced a new market research publication on Investigation Report on China Rituximab Market, 2009-2018. Rituximab (trade names “MabThera” by Roche, “Rituxan” by Genetech) is a chimeric monoclonal antibody against the protein … |
|
Investigation Report on China Rituximab Market, 2009-2018
PR Carbon (press release) FOR IMMEDIATE RELEASE, Illinois – United States – February 28,2014 (PR Carbon):Reportstack has announced a new market research publication on Investigation Report on China Rituximab Market, 2009-2018. Rituximab (trade names “MabThera” by … |
|
China Rituximab Market Investigation Report 2018 Forecasts
The International News Magazine Rituximab (trade names “MabThera” by Roche, “Rituxan” by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of Bcell lymphoma. As people … |
Idelalisib Shows Promising Activity in Heavily Pretreated iNHLOncLiveThe majority of patients (89%) had stage III or IV disease and all patients had not responded favorably to rituximab and an alkylating agent or had relapsed within 6 months of treatme…
|
Rituximab Doesn’t Alleviate Sjögren Symptoms at Week 24
Monthly Prescribing Reference (HealthDay News) — For patients with primary Sjögren syndrome (pSS), rituximab does not improve symptoms or disease activity at 24 weeks, according to a study published in the February 18 issue of the Annals of Internal Medicine. |
|
Doctors Warn Against Heart Problems in Non-Hodgkin’s Lymphoma Patients on …
PR Web (press release) Rituximab is a monoclonal antibody that is often used along with traditional chemotherapy in the treatment of Non-Hodgkin’s Lymphoma and other cancers involving the immune system B-cells. Doctors know that rituximab carries a risk of heart problems and … |
|
Doctors Warn Against Heart Problems in Non-Hodgkin’s Lymphoma Patients on …
DigitalJournal.com Rituximab is a monoclonal antibody that is often used along with traditional chemotherapy in the treatment of Non-Hodgkin’s Lymphoma and other cancers involving the immune system B-cells. Doctors know that rituximab carries a risk of heart problems and … |